ADA	adalimumab
ATI	antibodies to infliximab
CD	Crohn’s disease
EEN	exclusive enteral nutrition
EMA	European Medicine Agency
ESPGHAN	European Society of Pediatric Gastroenterology and Nutrition
FDA	Food and Drug Administration
HLH	hemophagocytic lymphohistiocytosis
HR	hazard ratio
HSTCL	hepatosplenic T-cell lymphoma
IBD	inflammatory bowel disease
IFX	infliximab
IV	intravenous
PCDAI	pediatric Crohn’s disease activity index
PUCAI	pediatric ulcerative colitis activity index
PYF	patient-years of follow-up
RCT	randomized controlled trial
SC	subcutaneous
SIR	standardized incidence ratio
SNPs	Single nucleotide polymorphisms
TDM	Therapeutic drug monitoring
UC	ulcerative colitis